The obesity penalty is now more expensive than a college degree

The labor market now puts a price on bodies that is larger than the price it puts on a degree.

In a 2026 NBER working paper, Harvard economist Rebecca Diamond measures that price: women who started taking a GLP-1 weight-loss medication saw their employment rate rise by nearly 27 percentage points over 18 months, a swing larger than the US employment gap between women with a high school diploma and women with a university degree. The naïve reading is that the drug unlocked something. The actual reading is that the door was narrower than anyone admitted.

Diamond's control group is the move that turns the number from a headline into a mechanism: women who wanted GLP-1 medications but had not yet started. Same desire, same labor market, same cycle. The only difference is whether a body had been re-read by the room. Diamond's own caveat is sharp. The change is in how women are perceived, not in skill, capability, or qualification. The lift is not a victory for the drug. It is a price tag on the obesity penalty, paid in hiring.

Eleven percent of US adults now take a GLP-1 to lose weight, up from 3% in 2024. The remedy does not live at the patient. It lives at the employer and at the law: structured interviews, blind resume screens, hiring-manager training, and the body-size anti-discrimination statutes already on the books in a handful of jurisdictions. The question Diamond's paper opens is not whether the drug works. It is who is doing the reading.